other material
confidence high
sentiment neutral
materiality 0.50
Inhibikase Therapeutics files prospectus supplement for $185M ATM offering via Jefferies
Inhibikase Therapeutics, Inc.
- Inhibikase may sell up to $185M of common stock under existing ATM program through Jefferies LLC.
- Prospectus supplement filed Dec 19, 2025, under registration statement on Form S-3 (File 333-288213).
- Sales Agreement with Jefferies LLC was originally dated June 20, 2025.
- No specific use of proceeds stated; offering conducted from time to time.